CTOs on the Move

Prothena

www.prothena.com

 
Prothena Corporation plc (Nasdaq: PRTA) Prothena is a global biotechnology company seeking to fundamentally alter the course of progressive diseases. We are a late-stage clinical company focused on the discovery, development, and commercialization of novel protein immunotherapies for the treatment of diseases that involve protein misfolding and inflammatory cell adhesion disorders. Our team has a recognized track record both for profound scientific discoveries and for the development of therapeutics that have become leading commercial products in their respective therapeutic categories. Prothena`s pipeline focuses on therapeutic monoclonal antibodies directed specifically to disease-causing proteins and our antibody-based product candidates target a ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.prothena.com
  • 331 Oyster Point Boulevard
    South San Francisco, CA USA 94080
  • Phone: 650.837.8550

Executives

Name Title Contact Details
Bill Yates
Vice President of Information Technology Profile

Funding

Prothena raised $155.3M on 03/03/2017
Prothena raised $67.8M on 03/24/2021

Similar Companies

The Coding Source LLC

The Coding Source LLC is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.

Personal Genome

Personal Genome Diagnostics (PGDx) is empowering the fight against cancer by unlocking actionable information from the genome. We are committed to developing a portfolio of regulated tissue-based and liquid biopsy genomic products for laboratories worldwide. Our expertise in advanced cancer genome analysis ranges from sample preparation and sequencing to data interpretation and analysis. We specialize in high-throughput next-generation sequencing, proprietary algorithms to identify alterations in complex cancer genomes and have developed novel technologies for non-invasive approaches in cancer. PGDx was founded in 2010 by Luis Diaz and Victor Velculescu to help bring novel diagnostic approaches to patients with cancer. They are internationally recognized leaders in cancer genomics who have extensive experience in the application of innovative genomic technologies for drug development and clinical practice.

Marina Biotech

Marina Biotech is a Bothell, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Halozyme

Halozyme is a biopharmaceutical company bringing disruptive solutions to significantly improve patient experiences and outcomes for emerging and established therapies. Halozyme advises and supports its biopharmaceutical partners in key aspects of new drug development with the goal of improving patients` lives while helping its partners achieve global commercial success. As the innovators of the ENHANZE® technology, which can reduce hours-long treatments to a matter of minutes, Halozyme`s commercially-validated solution has touched more than 500,000 patient lives in post-marketing use via five commercialized products across more than 100 global markets. Halozyme and its world-class partners are currently advancing multiple therapeutic programs intended to deliver innovative therapies, with the potential to improve the lives of patients around the globe. Halozyme`s proprietary enzyme rHuPH20 forms the basis of the ENHANZE® technology and is used to facilitate the delivery of injected drugs and fluids, potentially reducing the treatment burden of other drugs to patients. Halozyme has licensed its ENHANZE® technology to leading pharmaceutical and biotechnology companies including Roche, Baxalta, Pfizer, AbbVie, Lilly, Bristol-Myers Squibb, Alexion, argenx, Horizon Therapeutics and ViiV Healthcare. Halozyme derives revenues from these collaborations in the form of milestones and royalties as the Company`s partners make progress developing and commercializing their products being developed using ENHANZE®

Diazyme

Diazyme is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.